Claim 70% Off TipRanks Premium
- Unlock hedge fund-level data and powerful investing tools for smarter, sharper decisions
- Stay ahead of the market with the latest news and analysis and maximize your portfolio's potential
Nanjing Leads Biolabs Co., Ltd. Class H ( (HK:9887) ) has provided an announcement.
Nanjing Leads Biolabs Co., Ltd. has announced an extraordinary general meeting scheduled for December 17, 2025, to discuss several key resolutions, including the adoption of an H Share Award Scheme. This scheme aims to enhance the company’s stock management and incentivize stakeholders by allowing the issuance of new shares up to 5% of the current shares in issue. Additionally, the meeting will address the potential cancellation of the Supervisory Committee and amendments to the Articles of Association, which could streamline company governance and operational efficiency.
The most recent analyst rating on (HK:9887) stock is a Buy with a HK$80.27 price target. To see the full list of analyst forecasts on Nanjing Leads Biolabs Co., Ltd. Class H stock, see the HK:9887 Stock Forecast page.
More about Nanjing Leads Biolabs Co., Ltd. Class H
Nanjing Leads Biolabs Co., Ltd. is a joint stock company based in the People’s Republic of China, operating within the biotechnology industry. The company focuses on developing innovative biopharmaceutical products and services, with a market presence in the Hong Kong Stock Exchange under the stock code 9887.
Average Trading Volume: 702,493
Current Market Cap: HK$10.27B
Learn more about 9887 stock on TipRanks’ Stock Analysis page.